Rosetta, Agilent Alliance to Remain Intact After Merck Acquisition | GenomeWeb

NEW YORK, May 16 – Merck’s acquisition of Rosetta Inpharmatics will not affect the alliance between Rosetta and Agilent Technologies, an exclusive distributor of the Rosetta Resolver gene expression system, Merck and Agilent said Wednesday.

Following Merck’s acquisition of Rosetta, Agilent will continue to work with Rosetta as the only outside distributor of Rosetta Resolver, and will continue to work with Rosetta to develop gene expression technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.